Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 15/20 | 0.67 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etiproston SCHEMBL11602088 | 1.00 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Etiproston SCHEMBL12495605 | 1.00 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Etiproston SCHEMBL11603831 | 1.00 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Etiproston SCHEMBL11602481 | 1.00 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Etiproston SCHEMBL12495609 | 1.00 | PTGFR (0.67) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Etiproston SCHEMBL572165 | 0.94 | PTGFR (0.60) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL11602885 | 0.92 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL11601015 | 0.92 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL11602425 | 0.92 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| SCHEMBL11602179 | 0.92 | PTGFR (0.57) | PTGFRPTGER3TBXA2RPTGER1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113942-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2016-04-28 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2667875-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | Inceptum Research & Therapeutics, Inc. (CA) | 2013-12-04 | — | — | EP | claimed |
| US-20130309330-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2013-11-21 | — | — | US | claimed |
| WO-2012100347-A1 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS | INCEPTUM RESEARCH & THERAPEUTICS, INC. (CA) | 2012-08-02 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6353014-B1 | TREATMENT OF VISION DEFECTS WITH PROSTAGLANDINS | ALCON LABORATORIES, INC. | 2002-03-05 | — | — | US | claimed |
| US-20020010202-A1 | Combinations of prostaglandins and brimonidine or derivatives thereof | ALLERGAN SALES, INC. | 2002-01-24 | — | — | US | claimed |
| US-6294563-B1 | PROTECTION OF NERVES AND TREATING GLAUCOMA OR OCULAR HYPERTENSION | ALLERGAN SALES, INC. | 2001-09-25 | — | — | US | claimed |
| US-5811443-A | SIDE EFFECT REDUCTION | ALCON LABORATORIES, INC. (US) | 1998-09-22 | — | — | US | claimed |
| EP-0664707-B1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LAB INC (US) | 1997-06-04 | — | — | EP | claimed |
| US-5605922-A | VISION DISORDERS; SIDE EFFECT REDUCTION | ALCON LABORATORIES, INC. (US) | 1997-02-25 | — | — | US | claimed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | claimed |
| US-5480900-A | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010202-A1 | Combinations of prostaglandins and brimonidine or derivatives thereof | PTGER1, ADRB2, PTGS1 | PTGFR 80/4885PTGER3 18/4885TBXA2R 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.